658 related articles for article (PubMed ID: 26967328)
1. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
3. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
4. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).
Song Y; Wu YL; Cao LJ; Chen JH; Ma ZY; Cui JW; Wang J; Liu HB; Ding JY; Hu M
Am J Clin Oncol; 2019 May; 42(5):432-439. PubMed ID: 30950859
[TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
7. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
8. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
[TBL] [Abstract][Full Text] [Related]
9. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
Sutiman N; Tan SW; Tan EH; Lim WT; Kanesvaran R; Ng QS; Jain A; Ang MK; Tan WL; Toh CK; Chowbay B
J Thorac Oncol; 2017 Mar; 12(3):529-538. PubMed ID: 27908825
[TBL] [Abstract][Full Text] [Related]
10. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
[TBL] [Abstract][Full Text] [Related]
11. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
12. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
[TBL] [Abstract][Full Text] [Related]
13. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
[TBL] [Abstract][Full Text] [Related]
14. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
[TBL] [Abstract][Full Text] [Related]
15. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
[TBL] [Abstract][Full Text] [Related]
17. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
[TBL] [Abstract][Full Text] [Related]
18. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Watanabe S; Minegishi Y; Yoshizawa H; Maemondo M; Inoue A; Sugawara S; Isobe H; Harada M; Ishii Y; Gemma A; Hagiwara K; Kobayashi K
J Thorac Oncol; 2014 Feb; 9(2):189-94. PubMed ID: 24419415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]